Polaryx Therapeutics, Inc. Common Stock (PLYX) is a Healthcare stock trading at $2.08 (as of 2026-08-21), with a market capitalization of $103.68M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.
| Price | $2.08 |
| Market Cap | $103.68M |
| Price / Book | 9.48 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | VANGUARD CAPITAL MANAGEMENT LLC ($12.54M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Alex Yang |
| Employees | 11 |
| Country | US |
| IPO Date | 2026-02-02 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.